Literature DB >> 30872332

miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.

Mai Ashizawa1, Hirokazu Okayama2, Teruhide Ishigame3, Aung Kyi Thar Min1, Katsuharu Saito1, Daisuke Ujiie1, Yuko Murakami4, Tomohiro Kikuchi1, Yuko Nakayama1, Masaru Noda4, Takeshi Tada1, Hisahito Endo1, Shotaro Fujita1, Wataru Sakamoto1, Motonobu Saito1, Zenichiro Saze1, Tomoyuki Momma1, Shinji Ohki1, Kosaku Mimura1,5,6, Koji Kono1.   

Abstract

Immunotherapy against the interaction between programmed cell death 1/programmed cell death ligand 1 (PD-L1) has emerged as a promising strategy for colorectal cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). The study aimed to identify miRNAs that posttranscriptionally control PD-L1 expression on tumor cells and also regulate immune evasion. A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset (n = 260) combined with eight different miRNA target prediction programs resulted in the identification of a tumor suppressive miRNA, miR-148a-3p, as a potential negative regulator of PD-L1 expression, particularly in dMMR/MSI-H colorectal cancer. Using multiple cohorts of colorectal cancer, including TCGA data, a microarray dataset (n = 148), and formalin-fixed, paraffin-embedded samples (n = 395), we found that the expression of miR-148a-3p was decreased in dMMR/MSI-H tumors, correlating inversely with PD-L1 levels. We demonstrate that miR-148a-3p directly binds to the 3'-untranslated region of PD-L1, thereby reducing whole-cell and cell surface PD-L1 levels in HCT116 and SW837 cell lines. Overexpression of miR-148a-3p repressed IFNγ-induced PD-L1 expression on tumor cells and consequently diminished T-cell apoptosis in a coculture model of IL2-activated T cells and IFNγ-treated tumor cells. In conclusion, our data support a regulatory mechanism of PD-L1 expression on tumor cells and immune suppression via miR-148a-3p downregulation in colorectal cancer. IMPLICATIONS: This study provides novel evidence that miR-148a-3p negatively regulates tumor cell PD-L1 expression and decreased levels of miR-148a-3p contributes to the immunosuppressive tumor microenvironment. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30872332     DOI: 10.1158/1541-7786.MCR-18-0831

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  40 in total

1.  Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer.

Authors:  Aung Kyi Thar Min; Kosaku Mimura; Shotaro Nakajima; Hirokazu Okayama; Katsuharu Saito; Wataru Sakamoto; Shotaro Fujita; Hisahito Endo; Motonobu Saito; Zenichiro Saze; Tomoyuki Momma; Shinji Ohki; Koji Kono
Journal:  Cancer Immunol Immunother       Date:  2020-07-23       Impact factor: 6.968

2.  Depletion of tumor suppressor miRNA-148a in plasma relates to tumor progression and poor outcomes in gastric cancer.

Authors:  Shuhei Komatsu; Taisuke Imamura; Jun Kiuchi; Yusuke Takashima; Hajime Kamiya; Takuma Ohashi; Hirotaka Konishi; Atsushi Shiozaki; Takeshi Kubota; Kazuma Okamoto; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 3.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

Authors:  Hirohito Yamaguchi; Jung-Mao Hsu; Wen-Hao Yang; Mien-Chie Hung
Journal:  Nat Rev Clin Oncol       Date:  2022-02-07       Impact factor: 66.675

4.  Identification of a novel ceRNA network related to prognosis and immunity in HNSCC based on integrated bioinformatic investigation.

Authors:  Hongbo Liu; Guoli Hei; Lu Zhang; Yanxia Jiang; Haijun Lu
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

5.  Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis.

Authors:  Junjie Yin; Qingsong Yin; Bo Liang; Ruihua Mi; Hao Ai; Lin Chen; Xudong Wei
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-14       Impact factor: 3.000

Review 6.  miRNA dysregulation is an emerging modulator of genomic instability.

Authors:  Ana P Ferragut Cardoso; Mayukh Banerjee; Alexandra N Nail; Angeliki Lykoudi; J Christopher States
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

7.  Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2.

Authors:  Alison B Shupp; Manish Neupane; Lebaron C Agostini; Gang Ning; Jonathan R Brody; Karen M Bussard
Journal:  Mol Cancer Res       Date:  2021-05-21       Impact factor: 5.852

8.  MicroRNA-19b Downregulates NR3C1 and Enhances Oxaliplatin Chemoresistance in Colon Cancer via the PI3K/AKT/mTOR Pathway.

Authors:  Zhongbo Han; Chao Zhang; Qingfeng Wang; Liang Li; Meng Wang; Xi Li; Chunxia Yang
Journal:  Clin Med Insights Oncol       Date:  2021-05-05

9.  MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method.

Authors:  Zhengtian Li; Lingling Jiang; Rong Zhao; Jun Huang; Wenkang Yang; Zhenpei Wen; Bo Zhang; Gang Du
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

10.  miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.

Authors:  Anna Maria Grimaldi; Marco Salvatore; Mariarosaria Incoronato
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.